Drug & intervention

platinum

RxCUI 1311280

How to interpret these research links

Connected source records

CureCurrent currently connects this RxNorm drug concept to 14 displayed clinical trials and 13 distinct registered condition labels on this page. The links show what was studied, not whether this drug is effective or approved for those conditions. FDA-label excerpts, when available, refer to specific labeled products and may include route and formulation restrictions.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

What this record represents

IN · RxNorm

This is an RxNorm IN drug concept. Its name, formulation details and source identifiers are preserved to distinguish it from other drug records.

What this record does not establish: current marketing availability, therapeutic equivalence, safety, or official approval status. Check an up-to-date product label or a pharmacist for product-specific questions.

Inspect the RxNorm source identifier

Research activity for this drug concept

Published registry records

Study starts and current recruitment statuses across 14 distinct linked trials. This measures registered research activity, not medical effectiveness or FDA approval.

Reported start-year cohortsRegistered start year; the green segment is the subset reported as recruiting in the current snapshot. The current year may be incomplete.
All other statuses Currently recruiting
Current recruiting and other trial statusesCurrent ClinicalTrials.gov status snapshot for linked trials.
COMPLETED4 (28.6%)
NOT YET RECRUITING4 (28.6%)
ACTIVE NOT RECRUITING3 (21.4%)
UNKNOWN2 (14.3%)
RECRUITING1 (7.1%)

Related drug records

RxNorm name matches

These are other published drug concepts with matching brand or formulation names. They are not necessarily equivalent medicines.

No other matching drug records are currently published. This does not mean they do not exist in RxNorm.

Molecular structure

Verified RxNorm ingredient illustration
Molecular structure illustration of platinum
RxNorm RxCUI 1311280 · PubChem CID 23939 · Pt. Verify structure at PubChem. This drawing represents the matched chemical ingredient, not necessarily a complete multi-ingredient branded product.
Clinical trials14
Recruiting1
Related conditions13
Synonyms1
Advertisement

Clinical trials

14 shown
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 TrialNCT06256237 · 2024-04-01
RECRUITING
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNCT07376499 · 2026-01-25
NOT_YET_RECRUITING
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033NCT07097948 · 2025-08-01
NOT_YET_RECRUITING
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLCNCT06969027 · 2025-06-19
ACTIVE_NOT_RECRUITING
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNCT06951841 · 2025-04-30
NOT_YET_RECRUITING
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung CancerNCT06648200 · 2024-11-01
NOT_YET_RECRUITING
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCNCT05844150 · 2023-06-01
ACTIVE_NOT_RECRUITING
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）NCT04453930 · 2020-06-08
UNKNOWN
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLCNCT03607539 · 2018-08-23
COMPLETED
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung CancersNCT03567642 · 2018-06-12
ACTIVE_NOT_RECRUITING
Trial of BMS-986012 in Combination With Platinum and EtoposideNCT02815592 · 2016-11-28
COMPLETED
Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast CancerNCT02489409 · 2015-10-01
UNKNOWN
An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) PatientsNCT01844791 · 2012-09-01
COMPLETED
Randomized Gefitinib TrialNCT00807066 · 2008-11-01
COMPLETED

Conditions in registry-name-matched drug studies

ClinicalTrials.gov intervention names begin with this ingredient name. These are text matches, not verified RxNorm mappings, evidence of treatment efficacy, or approved indications. Different salts or formulations may be involved.

Non-small Cell Lung Cancer10 Non Small Cell Lung Cancer4 Small Cell Lung Cancer4 Non-Small-Cell Lung Cancer3 NSCLC3 Carcinoma, Non-Small-Cell Lung2 Advanced Lung Carcinoma1 Advanced Non Small Cell Lung Cancer (NSCLC)1 Advanced Non-squamous Non-small-cell Lung Cancer1 Advanced Solid Tumors1 Advanced Squamous Non-Small Cell Lung Carcinoma1 Autoimmune Disease1 Breast Neoplasms1 Cervical Cancer1 Colorectal Cancer1 CRC (Colorectal Cancer)1 Crohn Disease1 Dermatomyositis1 EGFR-mutant Non-small Cell Lung Cancer1 Extensive Stage Lung Small Cell Carcinoma1

Matching published trials

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVONCT03816345 · RECRUITING
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line RechallengeNCT04335292 · RECRUITING
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and DurvalumabNCT05568212 · RECRUITING
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)NCT05657873 · RECRUITING
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCNCT06216301 · RECRUITING
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 TrialNCT06256237 · RECRUITING
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLCNCT06424899 · RECRUITING
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerNCT06463665 · RECRUITING
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLCNCT06623656 · RECRUITING
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyNCT06769126 · RECRUITING
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung CancerNCT06865339 · RECRUITING
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerNCT06899126 · RECRUITING
ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung CancerNCT06902272 · RECRUITING
BBO-11818 in Adult Subjects With KRAS Mutant CancerNCT06917079 · RECRUITING
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLCNCT06977074 · RECRUITING
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerNCT07669779 · RECRUITING
Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung CancerNCT00112346 · COMPLETED
Randomized Gefitinib TrialNCT00807066 · COMPLETED
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung CancerNCT00883779 · COMPLETED
An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid TumorsNCT01040312 · COMPLETED
An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) PatientsNCT01844791 · COMPLETED
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung CancerNCT02031601 · UNKNOWN
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerNCT02299999 · ACTIVE NOT RECRUITING
Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast CancerNCT02489409 · UNKNOWN
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung CancerNCT02659059 · COMPLETED
Advertisement

Sponsors and collaborators in trials studying this drug

Links follow ClinicalTrials.gov trial associations; they do not identify the medicine's manufacturer or owner.

Shanghai Pulmonary Hospital, Shanghai, China 3 lead-sponsor trials · 0 collaborator trials 3 China Medical University, China 2 lead-sponsor trials · 0 collaborator trials 2 Biotheus Inc. 1 lead-sponsor trial · 0 collaborator trials 1 Bristol-Myers Squibb 1 lead-sponsor trial · 0 collaborator trials 1 Fondazione Humanitas per la Ricerca 1 lead-sponsor trial · 0 collaborator trials 1 Innovent Biologics (Suzhou) Co. Ltd. 1 lead-sponsor trial · 0 collaborator trials 1 Memorial Sloan Kettering Cancer Center 1 lead-sponsor trial · 0 collaborator trials 1 Oncozyme Pharma Inc. 1 lead-sponsor trial · 0 collaborator trials 1 Peking Union Medical College Hospital 1 lead-sponsor trial · 0 collaborator trials 1 Shanghai Junshi Bioscience Co., Ltd. 1 lead-sponsor trial · 0 collaborator trials 1 Xinjiang Medical University 1 lead-sponsor trial · 0 collaborator trials 1
Advertisement

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.